Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
International Urogynecology Journal

04-01-2025 | Botulinum Toxin | Original Article

Urodynamic Changes Following Fewer Injection Sites of Intravesical Botulinum Toxin in Idiopathic Detrusor Overactivity: A Double-Blinded Prospective Randomized Clinical Trial

Authors: Niloofar Soleimanifard, Reza Kaffash Nayeri, Mehran Moghimian, Sona Tayebi, Maryam Emami

Published in: International Urogynecology Journal

Login to get access

Abstract

Introduction and Hypothesis

This study was aimed at evaluating the therapeutic effects of a modified intravesical botulinum toxin injection technique (fewer injection sites under local anesthesia), in comparison with the conventional technique for patients with idiopathic detrusor overactivity, considering the urodynamic parameters.

Methods

In this double-blinded randomized clinical trial, 78 adult females with idiopathic detrusor overactivity were divided into two groups: conventional and modified groups. In the conventional method, patients received intradetrusor botulinum toxin injection at 20 sites under general or spinal anesthesia in a trigone-sparing fashion. In the modified group, injections were performed at five intradetrusor sites beyond the trigone, using local anesthetics. The primary end point was the comparison of urodynamic parameters in both groups following the procedure. The secondary endpoints were assessing the safety and tolerability of the modified method compared with the conventional method.

Results

There were no significant differences between the two treatment groups in terms of urodynamic parameters before the intervention (p > 0.05). After the intervention, no significant differences in urodynamic parameters were observed between the two treatment methods. All patients in the modified-method group could tolerate the procedure well.

Conclusion

The innovation of reducing the number of injection sites and concurrently using local anesthetics was shown to be as effective as the conventional method in terms of improving urodynamic parameters, tolerability, and safety in patients with idiopathic detrusor overactivity.
Appendix
Available only for authorised users
Literature
1.
Abrams P, Andersson K-E, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth international consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40.CrossRefPubMed
2.
Chen JL, Kuo HC. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol. 2020;61(Suppl 1):S33–42.CrossRefPubMed
3.
Apostolidis A, Papaefstathiou E, Gatsos S. Intravesical Botox for overactive bladder: how to minimize complications and manage failures. Curr Drug Targets. 2020;21(15):1527–36.CrossRefPubMed
4.
Stewart W, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.CrossRefPubMed
5.
6.
Liu H-T, Chancellor MB, Kuo H-C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009;56(4):700–7.CrossRefPubMed
7.
Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005;174(3):984–9.CrossRefPubMed
8.
Gong QQ, Xu YQ, Xu J, Ding XY, Guo C. Meta-analysis of randomized controlled trials using botulinum toxin A at different dosages for urinary incontinence in patients with overactive bladder. Front Pharmacol. 2020;15(10):1618.CrossRef
9.
Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–63.CrossRefPubMed
10.
Kelsey E, Wynn J, Holmes A, McLeod K. Anatomical location and number of injection sites of intravesical OnabotulinumtoxinA for females with refractory idiopathic overactive bladder: a scoping review. Neurourol Urodyn. 2024;7:100957.
11.
Defreitas GA, Zimmern PE, Lemack GE, Shariat SF. Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology. 2004;64(4):675–9.CrossRefPubMed
12.
Rosier PF, Schaefer W, Lose G, Goldman HB, Guralnick M, Eustice S, Dickinson T, Hashim H. International Continence Society Good Urodynamic Practices and Terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36(5):1243–60.CrossRefPubMed
13.
Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181(6):2608–15.CrossRefPubMedPubMedCentral
14.
Rapp DE, Lucioni A, Bales GT. Botulinum toxin injection: a review of injection principles and protocols. Int Braz J Urol. 2007;33:132–41.CrossRefPubMed
15.
Avallone MA, Sack BS, El-Arabi A, Guralnick ML, O'Connor RC. Less is more—A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity. Neurourol Urodyn. 2017;36(4):1104–7.CrossRefPubMed
16.
Karsenty G, Carsenac A, Boy S, Reitz A, Bardot P, Tournebise H, et al. Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)-A prospective randomized study to compare 30 vs. 10 injection sites. Eur Urol Suppl. 2007;2(6):245.CrossRef
17.
Coelho A, Cruz F, Cruz CD, Avelino A. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol. 2012;61(6):1178–84.CrossRefPubMed
18.
Chen S-F, Chang C-H, Kuo H-C. Clinical efficacy and changes of urothelial dysfunction after repeated detrusor botulinum toxin A injections in chronic spinal cord-injured bladder. Toxins. 2016;8(6):164.CrossRefPubMedPubMedCentral
19.
Mehnert U, Boy S, Schmid M, Reitz A, von Hessling A, Hodler J, Schurch B. A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol. 2009;27(3):397–403.CrossRefPubMed
20.
Liao CH, Chen SF, Kuo HC. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study. Neurourol Urodyn. 2016;35(6):717–23.CrossRefPubMed
21.
Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units Dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2017;36(2):457–62.CrossRefPubMed
22.
Martínez-Cuenca E, Bonillo MA, Morán E, Broseta E, Arlandis S. OnabotulinumtoxinA re-injection for refractory detrusor overactivity using 3–4 injection sites: results of a pilot study. Urology. 2020;137:50–4.CrossRefPubMed
23.
Ton J, Downing P, Versi E, van Uem S, Ephraim S, Murphy M, Lucente V. Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB). Int Urol Nephrol. 2021;53(6):1067–72.CrossRefPubMed
24.
Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014;65(5):981–90.CrossRefPubMed
25.
Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43:16–24.CrossRef
Metadata
Title
Urodynamic Changes Following Fewer Injection Sites of Intravesical Botulinum Toxin in Idiopathic Detrusor Overactivity: A Double-Blinded Prospective Randomized Clinical Trial
Authors
Niloofar Soleimanifard
Reza Kaffash Nayeri
Mehran Moghimian
Sona Tayebi
Maryam Emami
Publication date
04-01-2025
Publisher
Springer International Publishing
Keyword
Botulinum Toxin
Published in
International Urogynecology Journal
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-024-06009-6

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Image Credits